Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) went up by 2.39% from its latest closing price compared to the recent 1-year high of $20.48. The company’s stock price has collected 9.44% of gains in the last five trading sessions.
Is It Worth Investing in Y-mAbs Therapeutics Inc. (NASDAQ :YMAB) Right Now?
Plus, the 36-month beta value for YMAB is at 0.74. Opinions of the stock are interesting as 6 analysts out of 10 who provided ratings for Y-mAbs Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $14.63, which is $9.49 above the current price. YMAB currently public float of 38.06M and currently shorts hold a 8.08% ratio of that float. Today, the average trading volume of YMAB was 599.98K shares.
YMAB’s Market Performance
YMAB stocks went up by 9.44% for the week, with a monthly drop of -71.72% and a quarterly performance of -74.69%, while its annual performance rate touched -75.12%. The volatility ratio for the week stands at 8.43% while the volatility levels for the past 30 days are set at 16.88% for Y-mAbs Therapeutics Inc. The simple moving average for the period of the last 20 days is -9.93% for YMAB stocks with a simple moving average of -65.27% for the last 200 days.
Analysts’ Opinion of YMAB
Many brokerage firms have already submitted their reports for YMAB stocks, with Wedbush repeating the rating for YMAB by listing it as a “Neutral.” The predicted price for YMAB in the upcoming period, according to Wedbush is $6 based on the research report published on October 31st of the current year 2022.
JP Morgan, on the other hand, stated in their research note that they expect to see YMAB reach a price target of $7, previously predicting the price at $16. The rating they have provided for YMAB stocks is “Underweight” according to the report published on October 31st, 2022.
Canaccord Genuity gave a rating of “Buy” to YMAB, setting the target price at $35 in the report published on July 06th of the current year.
YMAB Trading at -59.20% from the 50-Day Moving Average
After a stumble in the market that brought YMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.05% of loss for the given period.
Volatility was left at 16.88%, however, over the last 30 days, the volatility rate increased by 8.43%, as shares sank -61.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -71.40% lower at present.
During the last 5 trading sessions, YMAB rose by +9.44%, which changed the moving average for the period of 200-days by -38.01% in comparison to the 20-day moving average, which settled at $4.43. In addition, Y-mAbs Therapeutics Inc. saw -73.53% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at YMAB starting from Rajah Vignesh, who purchase 1,195 shares at the price of $4.92 back on Nov 15. After this action, Rajah Vignesh now owns 4,266 shares of Y-mAbs Therapeutics Inc., valued at $5,884 using the latest closing price.
Kruse Bo, the EVP, CFO, Secretary & Treas. of Y-mAbs Therapeutics Inc., sale 4,000 shares at $7.85 during a trade that took place back on Feb 22, which means that Kruse Bo is holding 181,077 shares at $31,400 based on the most recent closing price.
Stock Fundamentals for YMAB
Current profitability levels for the company are sitting at:
- -330.78 for the present operating margin
- +92.80 for the gross margin
The net margin for Y-mAbs Therapeutics Inc. stands at -158.39. Equity return is now at value -92.70, with -75.00 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 7.26.